ERC Consolidator Grant · 2019
Chirality via Cross-Coupling: New Asymmetric C-C Bond Formations Driven by Atom and Step Economy
Over 60% of the world’s top selling small molecule drug compounds are chiral and, of these, approximately 80% are marketed as single enantiomers. Surprisingly, and despite the tremendous advances made in catalysis over the past several decades, the average “chiral complexity” of drug discovery libraries has actually decreased, while, at the same time the “chiral complexity” of marketed drugs has increased. Consequently, there is now an urgent need to provide efficient processes that access directly privileged chiral “3D” building blocks. It is our philosophy that catalysis holds the key here and new processes should be based upon atom and step economical platforms that exert control over…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.